BRPI0910232A2 - formas de sais inibidores do mtor - Google Patents

formas de sais inibidores do mtor

Info

Publication number
BRPI0910232A2
BRPI0910232A2 BRPI0910232A BRPI0910232A BRPI0910232A2 BR PI0910232 A2 BRPI0910232 A2 BR PI0910232A2 BR PI0910232 A BRPI0910232 A BR PI0910232A BR PI0910232 A BRPI0910232 A BR PI0910232A BR PI0910232 A2 BRPI0910232 A2 BR PI0910232A2
Authority
BR
Brazil
Prior art keywords
salt forms
inhibitor salt
inhibitor
forms
salt
Prior art date
Application number
BRPI0910232A
Other languages
English (en)
Inventor
Arlindo L Castelhano
Gary C Visor
Josef A Rechka
Kristen Michelle Mulvihill
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of BRPI0910232A2 publication Critical patent/BRPI0910232A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0910232A 2008-03-19 2009-03-18 formas de sais inibidores do mtor BRPI0910232A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7006208P 2008-03-19 2008-03-19
PCT/US2009/037505 WO2009117482A1 (en) 2008-03-19 2009-03-18 Mtor inhibitor salt forms

Publications (1)

Publication Number Publication Date
BRPI0910232A2 true BRPI0910232A2 (pt) 2015-09-29

Family

ID=40597405

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910232A BRPI0910232A2 (pt) 2008-03-19 2009-03-18 formas de sais inibidores do mtor

Country Status (12)

Country Link
US (1) US8557814B2 (pt)
EP (1) EP2276763A1 (pt)
JP (1) JP2011515410A (pt)
KR (1) KR20110017845A (pt)
CN (1) CN101977912A (pt)
AU (1) AU2009225614A1 (pt)
BR (1) BRPI0910232A2 (pt)
CA (1) CA2716924A1 (pt)
EA (1) EA018144B1 (pt)
MX (1) MX2010010300A (pt)
WO (1) WO2009117482A1 (pt)
ZA (1) ZA201006641B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148491A (en) * 2005-11-17 2013-04-30 Osi Pharm Inc FUSED BICYCLIC mTOR INHIBITORS
US20090274698A1 (en) * 2007-07-06 2009-11-05 Shripad Bhagwat Combination anti-cancer therapy
EP2276763A1 (en) 2008-03-19 2011-01-26 OSI Pharmaceuticals, Inc. Mtor inhibitor salt forms
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
EA036876B1 (ru) 2009-11-05 2020-12-30 Ризен Фармасьютикалз С.А. Ингибиторы pi3k киназы
US20130005733A1 (en) 2010-03-09 2013-01-03 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
SG192576A1 (en) 2011-02-23 2013-09-30 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
CA2833935C (en) 2011-05-04 2020-09-15 Dhanapalan Nagarathnam Novel compounds as modulators of protein kinases
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
SI3260455T1 (sl) 2012-07-04 2019-07-31 Rhizen Pharmaceuticals S.A. Selektivni inhibitorji PI3K-delta
JP2016527227A (ja) * 2013-07-16 2016-09-08 ドクター レディズ ラボラトリーズ リミテッド ペメトレキセドトロメタミン塩の新規な結晶形
EA032779B1 (ru) * 2014-03-06 2019-07-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
US10023576B2 (en) 2014-10-22 2018-07-17 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
WO2016064957A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
HRP20231614T1 (hr) 2016-03-28 2024-03-15 Incyte Corporation Spojevi pirolotriazina kao tam inhibitori
WO2020032951A1 (en) 2018-08-09 2020-02-13 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
FR3075795A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075794A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1046731C (zh) * 1994-09-29 1999-11-24 诺瓦蒂斯有限公司 吡咯并[2,3-d]嘧啶类化合物及其应用
DE69815317T2 (de) * 1997-03-19 2005-04-07 Abbott Gmbh & Co. Kg Pyrrolo[2,3-d]pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
ES2206191T3 (es) * 1999-01-11 2004-05-16 Princeton University Inhibidores de alta afinidad para validacion de dianas y usos de los mismos.
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
EP1425284A2 (en) * 2001-09-11 2004-06-09 Smithkline Beecham Corporation Furo- and thienopyrimidine derivatives as angiogenesis inhibitors
AU2004282219C1 (en) * 2003-10-15 2009-12-17 Osi Pharmaceuticals, Inc. Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
WO2005054268A1 (en) * 2003-10-27 2005-06-16 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
JP2007511596A (ja) * 2003-11-17 2007-05-10 ファイザー・プロダクツ・インク 癌の治療において有用なピロロピリミジン化合物
CA2561950C (en) * 2004-04-02 2010-04-20 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
AR053090A1 (es) * 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
JP2008520744A (ja) * 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
MY148491A (en) * 2005-11-17 2013-04-30 Osi Pharm Inc FUSED BICYCLIC mTOR INHIBITORS
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2007079164A2 (en) * 2005-12-29 2007-07-12 Abbott Laboratories Protein kinase inhibitors
EP1981890A2 (en) * 2006-01-25 2008-10-22 OSI Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
EP1996193A2 (en) * 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
CN101460161A (zh) 2006-03-29 2009-06-17 弗尔德里克斯制药股份有限公司 α-突触核蛋白毒性的抑制
PT2004654E (pt) * 2006-04-04 2013-08-27 Univ California Derivados de pirazolopirimidina para utilização como antagonistas da quinase
DE102006016426A1 (de) 2006-04-07 2007-10-11 Merck Patent Gmbh Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
EP2173338A1 (en) * 2007-07-06 2010-04-14 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy
US20090274698A1 (en) * 2007-07-06 2009-11-05 Shripad Bhagwat Combination anti-cancer therapy
AU2008313504A1 (en) * 2007-10-15 2009-04-23 Astrazeneca Ab Combination 059
EP2276763A1 (en) 2008-03-19 2011-01-26 OSI Pharmaceuticals, Inc. Mtor inhibitor salt forms
EP2451792A4 (en) 2009-07-09 2013-03-06 Osi Pharmaceuticals Llc PROCESS FOR THE PRODUCTION OF SUBSTITUTED 3-AMINO-5-OXO-4,5-DIHYDRO- [1,2,4] TRIAZINES
JP2013500991A (ja) 2009-07-31 2013-01-10 オーエスアイ・ファーマシューティカルズ，エルエルシー ｍＴＯＲ阻害剤および血管新生阻害剤併用療法

Also Published As

Publication number Publication date
EA201071099A1 (ru) 2011-02-28
KR20110017845A (ko) 2011-02-22
CA2716924A1 (en) 2009-09-24
ZA201006641B (en) 2011-05-25
US8557814B2 (en) 2013-10-15
US20110015197A1 (en) 2011-01-20
EP2276763A1 (en) 2011-01-26
WO2009117482A1 (en) 2009-09-24
AU2009225614A1 (en) 2009-09-24
MX2010010300A (es) 2010-10-26
WO2009117482A8 (en) 2010-04-08
JP2011515410A (ja) 2011-05-19
CN101977912A (zh) 2011-02-16
EA018144B1 (ru) 2013-05-30

Similar Documents

Publication Publication Date Title
BRPI0910232A2 (pt) formas de sais inibidores do mtor
CY2020023I2 (el) Αναστολεiς βητα-λακταμασων
BRPI0922466A2 (pt) sais
BRPI0917808A2 (pt) inibidores de cmet
BRPI0906764A2 (pt) Processos
BRPI0821868A2 (pt) Grânulo
BRPI0911175A2 (pt) conjuntos de válvula
BRPI0908115A2 (pt) torneira
BRPI0919591A2 (pt) válvula magnética
BRPI0914781A2 (pt) Microbiocidas
BRPI0924163A2 (pt) kit de limpeza de arma de fogo
BRPI0918564A2 (pt) inibidores
BRPI0908513A2 (pt) válvula
BRPI0911625A2 (pt) Métodos
FR2914943B1 (fr) Aube de soufflante
BRPI0911199A2 (pt) microbiocidas
BRPI0821901A2 (pt) Válvula homogeneizadora
BRPI0909106A2 (pt) Método herbicida
BRPI0918966A2 (pt) inibidores de protease
BRPI0912564A2 (pt) inibidores de jnk
DE602007002163D1 (de) Weichspülmittel
IT1394067B1 (it) Valvola
BRPI0914616A2 (pt) herbicidas
BRPI0919073A2 (pt) inibidores de protease
BRPI0919801A2 (pt) revestimento ii

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.